Harbour BioMed, Vir to develop new therapies

By The Science Advisory Board staff writers

August 24, 2020 -- Harbour Biomed (HBM) and Vir Biotechnology have partnered to research and develop novel immuno-oncology and infectious disease therapies.

The partnership will leverage the scientific expertise at both companies in order to develop immunotherapies for patients with cancer and infectious disease. It will also utilize HBM's Harbour Mice technology to generate antibodies for the experiments.

Copyright © 2020 scienceboard.net

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.